Anavex Life Sciences (AVXL) Releases Earnings Results
Anavex Life Sciences (NASDAQ:AVXL) posted its quarterly earnings results on Monday. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02), Bloomberg Earnings reports.
Shares of Anavex Life Sciences (AVXL) opened at $3.30 on Tuesday. Anavex Life Sciences has a 12-month low of $3.01 and a 12-month high of $6.64.
AVXL has been the topic of a number of recent research reports. Zacks Investment Research cut Anavex Life Sciences from a “buy” rating to a “hold” rating in a report on Friday, August 18th. ValuEngine cut Anavex Life Sciences from a “hold” rating to a “sell” rating in a report on Thursday, September 28th. Noble Financial reiterated a “buy” rating and issued a $15.00 target price on shares of Anavex Life Sciences in a report on Friday, September 29th. Finally, Maxim Group set a $15.00 target price on Anavex Life Sciences and gave the stock a “buy” rating in a report on Thursday, October 12th.
An institutional investor recently raised its position in Anavex Life Sciences stock. The Manufacturers Life Insurance Company boosted its stake in Anavex Life Sciences Corp. (NASDAQ:AVXL) by 37.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 31,876 shares of the biotechnology company’s stock after buying an additional 8,728 shares during the quarter. The Manufacturers Life Insurance Company owned approximately 0.08% of Anavex Life Sciences worth $169,000 as of its most recent SEC filing. 23.88% of the stock is owned by hedge funds and other institutional investors.
Anavex Life Sciences Company Profile
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.
Receive News & Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related companies with MarketBeat.com's FREE daily email newsletter.